Stereotaxis Inc. (STXS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, STXS scores 22 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 5/20, reflecting a ROIC of -35% and an FCF yield of -15.01%, which indicates the business is not currently generating cash returns on invested capital. The Whale 13F Flow pillar scores 3/20 and the Insider Conviction pillar scores 3/20; the rating notes institutional accumulation and options positioning and SEC Form 4 and Congressional PTR cluster flow as the basis for these scores, but the underlying holder and insider records are not provided in the source data for this brief. The Macro Regime Fit pillar scores 3/20, with a beta of 1.0 and a sector sensitivity note. The Forensic Balance Sheet pillar scores 8/20, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the rating's emphasis is that the weakest pillars are cash generation and conviction signals, while the balance sheet is the relatively stronger pillar. Potential upside drivers would need to come from a turn toward positive ROIC and FCF, which the data does not show. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. The rating is an educational summary of the cited metrics, not a recommendation.

Stereotaxis Inc. (STXS) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the company profile, its market capitalization is $0.1B. The source data does not detail its specific products, customer base, or revenue model beyond the sector and industry classification and the headline references to robotic magnetic navigation systems and partnerships in the news wire.

Per the SEC financials, revenue increased from $26.9M in FY 2024 to $32.4M in FY 2025, while operating and net losses remained substantial in each reported period. The gross margin is 52.7%, but operating and net margins are both -60%, and ROIC is -35%, per the market data. The Altman Z-Score of 2.5 and Piotroski F-Score of 5/9 are cited in the Roarable RQD rating, and the Debt/Equity ratio of 0.5 is part of the forensic balance sheet pillar. Reported cash rose to $13.4M in FY 2025 from $12.2M in FY 2024. Debt is not available in source data for the reported periods.

Per the recent news feed, the most recent items include a scheduled announcement that Stereotaxis will report third quarter 2026 financial results on November 10, 2026, which is a near-term event for watchers of the company. A report on Latvia's first robotic heart-rhythm program treating its first patients is labeled as a market wire item. A news item describes Pauls Stradins Clinical University Hospital installing a Genesis robotic magnetic navigation system, and a separate item describes a Canon Medical and Stereotaxis partnership on imaging and robotics, which carries a green CATALYST label in the feed. A StockInvest.us forecast piece and a Yahoo Finance UK seasonal returns chart are also present but contain no company-specific fundamental detail. The butterfly supply-chain graph reports no supply-chain relationships and no proprietary signals, so no graph-derived ripple analysis is available.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlation links are therefore not available in source data. Investors should watch whether the Canon Medical partnership and hospital system installations referenced in the news feed translate into disclosed revenue or supply-chain commitments in future filings, since the source data does not quantify either.

• What are the company's P/E, forward P/E, EV/EBITDA, and EPS figures, given that these valuation metrics are absent from the source data?
• What is the company's debt level for each reported period, since debt is listed as N/A throughout the financials?
• What specific institutional and insider transactions underlie the whale 13F and insider conviction pillar scores?
• Will the Canon Medical partnership and hospital installations produce disclosed revenue, and at what scale?
• What is the company's path to positive ROIC and free cash flow, given the -35% ROIC and -15.01% FCF yield?